Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. We investigated in vivo glioblastoma models charact...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Xie, Qian, Bradley, Robert, Kang, Liang, Koeman, Julie, Ascierto, Maria Libera, Worschech, Andrea, De Giorgi, Valeria, Wang, Ena, Kefene, Lisa, Su, Yanli, Essenburg, Curt, Kaufman, Dafna W., DeKoning, Tom, Enter, Mark A., O'Rourke, Timothy J., Marincola, Francesco M., Vande Woude, George F.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2012
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3258605/
https://ncbi.nlm.nih.gov/pubmed/22203985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1119059109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars